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Studies were conducted in northern Bohemia to simultaneously evaluate personal exposures to
air pollution in the form of respirable particles containing polycyclic aromatic hydrocarbons (PAHs)
and biomarkers of exposure, biological effective dose, genetic effects, and metabolic susceptibil-
ity. The series of biomarkers included PAH metabolites in urine, urine mutagenicity, PAH-DNA
adducts in white blood cells determined by32P-postlabeling, PAH-albumin adducts determined by
enzyme-linked immunosorbent assay (ELISA), DNA damage in lymphocytes detected by comet
assay, chromosomal aberrations, sister chromatid exchanges, and glutathione S-transferase Ml
(GSTM1) genotypes. For these studies, a group of women who work outdoors about 30% of
their daily time was selected. In a pilot study, a group of women from a polluted area of the
Teplice district (northern Bohemia) was compared with a group of women from a control district
of southern Bohemia (Prachatice). In a follow-up repeated-measures study, a group of nonsmoking
women from Teplice was sampled repeatedly during the winter season of 1993 to 1994.
Personal exposure monitoring for respirable particles (<2.5 pm) was conducted for the 24-hr
period before collection of blood and urine. Particle extracts were analyzed for carcinogenic PAHs.
In the pilot study and in the follow-up study, a highly significant correlation between individual
personal exposures to PAHs and DNA adducts was found (r=0.54, p=0.016; r=0.710, p<0.001,
respectively). The comet parameter (percentage DNA in tail; %T) correlated with exposures to
respirable particles (r=0.304, p=0.015). The GSTM1 genotype had a significant effect on urinary
PAH metabolites, urine mutagenicity, and comet parameters (%T and tail moment) when the
GSTM1 genotype was considered as a single factor affecting these biomarkers. Multifactor analysis
of variance considering exposure and adjusting the data for GSTM1, age, and diet showed that
the effect of personal exposures to PAHs on the variability of biomarkers (DNA adducts, comet
parameters, urine mutagenicity) might be higher than the effect of the GSTM1 genotype. These
results show the importance of considering all potential factors that may affect the biomarkers
being analyzed. Environ Health Perspect 104(Suppl 3):591-597 (1996)
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Introduction
Northern Bohemia, a highly industrialized
brown coal basin, was one of the most
polluted areas in all ofEurope (1). High-
sulfur brown coal is used not only by
power plants (this area produced 35%
of the electricity used in the former
Czechoslovakia), glasswork, and chemical
and petrochemical industries but also for
heating homes, large apartment complexes,
and business facilities. In addition to
industry, heavy automobile traffic en route
to Germany contributes to the air pollution
in this area. The health consequences of
environmental pollution are a major con-
cern of the Czech Government and the
public. Early studies provided evidence ofa
high incidence ofcancer and reproductive
and behavioral effects (2,3). Teplice, one of
the mining districts in northern Bohemia,
was designated in 1991 as a model district
for improved environmental monitoring
and research on the health effects ofair pol-
lution as part ofa large interdisciplinary
project called the Teplice Program. The
studies reported here are part ofthe project
Biomarkers ofExposure to Mutagens and
Carcinogens. The objectives ofthis project
are to simultaneously evaluate personal
exposures and internal measures ofexpo-
sure, biological effective dose, early biologi-
cal effects, and metabolic susceptibility
using a series ofbiomarkers.
The first studies in which biomarkers
detected seasonal differences in exposure
and genetic damage from environmental
pollution were conducted in a population
from a highly polluted area in Silesia
(Poland) (4-7). In these studies, the inves-
tigators were not able to determine the rela-
tionship between individual exposure to air
pollution and biomarkers ofexposure and
genetic damage because personal exposure
datawere not collected.
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In our studies, polycyclic aromatic
hydrocarbons (PAHs) were selected as the
air pollution marker for monitoring of
personal exposures. PAHs and their nitro-
derivates associated with respirable particle
fraction (RSP) have been identified as a
major source ofcarcinogenic risk in urban
areas (8,9). An air quality monitoring and
receptor modeling study (10) conducted in
the Teplice district during 1992 to 1994
identified emissions from residential heating
and vehicles as the major sources oforganic
carbon, including carcinogenic PAHs.
These compounds are primarily activated
through an oxidative metabolic pathway to
electrophilic intermediates capable ofcova-
lent binding to protein and DNA. Further-
more, theyare detoxified by the glutathione
transferase enzymes from the glutathione
S-transferase (GST) genes (e.g., glutathione
S-transferase Ml [GSTM ]).
On the basis of this knowledge, the
following exposure and dosimetry bio-
markers were selected for our studies. The
PAH metabolites in urine and urine muta-
genicity were used as markers ofinternal
exposure reflecting uptake, metabolism,
and excretion. PAH-DNA adducts detected
by 32P-postlabeling and PAH-albumin
adducts detected by enzyme-linked immu-
nosorbent assay (ELISA) were used as
markers of biological effective dose.
Selected biomarkers of genetic damage
include chromosomal aberrations (CA) and
sister chromatid exchanges (SCE) evaluated
by cytogenetic analysis. GSTM1 genotypes
were determined as one of the markers of
metabolic susceptibility.
A population ofwomen who worked
outdoors about 30% oftheir daily time was
selected for our studies. In a pilot study, a
group ofwomen working as postal workers
or gardeners from a highly polluted area of
the Teplice district was compared with the
group ofwomen working as postal workers
and nursery school teachers in the town of
Prachatice, a control district in southern
Bohemia (11). There were 21 nonsmokers
and 9 light smokers in the Teplice group
and 30 nonsmokers in the Prachatice
group. We did not find any significant dif-
ferences in DNA and protein adducts,
SCE, and the urinary mutagenicity results
when nonsmokers from these two districts
were compared; CA was an exception. The
higher values of CA in the control group
from Prachatice resulted from elevations
only in the nursery school teachers. The
measurement for exposure to carcinogenic
PAHs indicated significantly lower expo-
sure in the control district, as reflected in
the urinary PAHs and metabolites; how-
ever, the range of exposures overlapped
between these two districts. The higher
mutagenic response was observed in the
urine ofsmokers in all mutation assays as
compared to nonsmokers from the both
districts, but these data were not significant
due to high interindividual variability
within this relatively small group (12).
Within the nonsmokers from Teplice,
significant correlation ofpersonal exposure
to carcinogenic PAHs with DNA adducts
was found (r=0.54,p=0.016) (13).
Based on the results obtained in the pilot
study, we started a follow-up study with a
group ofnonsmokingwomen from the town
ofTeplice. This report is an update ofthe
ongoing investigation providing information
about the relationship between individual
environmental exposures to carcinogenic
PAHs, the GSTM1 genotype, and bio-
markers ofexposure and genetic damage.
Methods
Subjects andSampling
Informed consent was obtained from each
subject prior to beginning this study. A
questionnaire was administered to each
subject to determine her individual
lifestyle (e.g., diet, smoking habits, passive
smoking exposure, alcohol consumption,
residence in district). Any persons with
medical treatment, radiography, or vacci-
nation within the previous 3 months were
not included in the study.
In the pilot study, a group of30 women
from Teplice city from 18 to 51 years of
age (median= 36 years) and 30 women
from Prachatice city from 28 to 54 years of
age (median =42 years) were selected, as
described in detail elsewhere (11). Most of
the subjects were lifetime residents ofthese
districts. In the Teplice group, 9 women
were smokers (smoking 3-15 cigarettes/
day), whereas women in the Prachatice
group were all nonsmokers. The pilot study
was conducted during the last week of
November 1992 in Teplice and the first
week ofDecember 1992 in Prachatice and
lasted 2 days for each group.
In this study we selected 19 nonsmok-
ing women from 18 to 52 years of age
(median= 31.5 years) with residence in
Teplice city (13 postal workers and 6 gar-
deners). Ten ofthese womenwere also part
ofthe pilot study. The nonsmoking status
was verified by determination of cotinine
in urine samples using radioimmunoassay
(14). The study was performed during the
winter season and included 4 sampling
days (whole group sampled in 1 day) from
the end of October 1993 until February
1994, when this study was interrupted
due to a long period of unusual meteoro-
logical conditions (high wind and lack of
inversion conditions).
Personal exposure monitoring (PEM),
starting at the beginning of the working
shift, was conducted for 24 hr. Blood
and urine samples were collected at the end
ofPEM.
PersonalExposure Monitoring
Personal monitoring was provided using a
personal sampler from the U.S. Environ-
mental Protection Agency (U.S. EPA)
(15,16). Respirable particles smaller than
2.5 pm were collected on Teflon-impreg-
nated glass fiber filters. The sampler was
connected to a pump powered by batteries
and operated continuously for a 24-hr
period. The sampler inlet was attached to
the individual near the breathing zone and
was located by her bed during the night.
Particles from the filter were extracted by
sonication with dichloromethane for analy-
sis ofthe carcinogenic PAHs byhigh-perfor-
mance liquid chromatography (HPLC) with
fluorimetric detection (17). The carcino-
genic PAHs reported here include chrysene,
benzo[a]anthracene, benzo[b]fluoranthene,
benzo[k]fluoranthene, benzo[a]pyrene,
dibenzo[ah]anthracene, indeno[1,2,3-
cd]pyrene and benzo[ghi]perylene. Detailed
sampling and analytical methods are
reported elsewhere (11,15-17).
UrineMutAgenicityand
PAH MetaboliteAnalysis
Urine samples were tested for mutagenicity
in the plate incorporation assay using tester
stains TA98 and YG1041 and in the Kado-
microsuspension assay using the YG1041
strain because these strains are the most
sensitive to PAHs and nitro-PAHs present
in air samples from north Bohemia (16).
Both assays were performed with and with-
out metabolic activation. The detailed pro-
cedures are described byCerni et al. (12).
For detection and quantitation of the
parent PAHs and their metabolites (PAH/
metabolite) in urine, two independent
methods (HPLC and gas chromatography-
mass spectrometry) were used as described
in detail by Lewtas et al. (11).
DNAAdductAnalysis
by32p-posdabeling
White blood cells (WBC) were isolated from
fresh heparinized blood by centrifugation
at 900xgfor 20 min followed by lysing of
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the contaminating red cells. DNA was
isolated, as previously described (18),
using RNAses A and Ti and proteinase K
treatment followed by phenol/chloroform/
isoamylalcohol extraction.
DNA adducts were analyzed by 32P-
postlabeling according to the method of
Gupta et al. (19) with minor modifications
as described in detail elsewhere (13).
Briefly, 3.0 pg DNA was enzymatically
hydrolyzed to 3'-nucleoside monophos-
phates. The adducted nucleotides were
enriched by butanol extraction (18).
Adducts were labeled with [y-32P]ATP in
the presence ofT-4 polynucleotide kinase.
The radiolabeled samples were analyzed by
multidimensional PEI-cellulose thin-layer
chromatography (TLC). To calculate
adduct levels, the aliquots of DNA enzy-
matic digestion product from each individ-
ual sample were labeled with the same
radiolabeled mix. Intensifying screen-
enhanced autoradiography was used to
detect the presence ofradiolabeled adducts
on TLC plates. The total DNA adduct
levels reported here are for the diagonal
radioative zone (DRZ), inclusive ofall dis-
tinctive spots, and were evaluated from at
least two independent experiments from
the pilot or follow-up studies.
PAH-ProteinAdducts
byCompetitive ELISA
Competitive ELISA with the monoclonal
antibody 8E1 1 (20) was used to analyze
for benzo[a]pyrene (B[a]P) tetrols released
from plasma albumin, basically as described
by Lee and Santella (21) with modifica-
tions described in detail elsewhere (11).
The values for each subject are the mean of
two replicate wells and are expressed as
femtomoles ofB[a]P tetrols per microgram
protein. Samples with less than 20% inhi-
bition in the ELISA were considered to be
below detectable limits, and the concentra-
tions corresponding to 10% inhibition on
the standard curve were assigned to these
samples for statistical analysis.
CytogeneticAnalysis
Lymphocyte cultures were prepared from
the whole blood as previously described
by Sorsa et al. (22). The microscopic slides
were stained with Giemsa (for detection of
CA) or with fluorescence plus Giemsa (for
detection ofSCE). Chromosomal aberra-
tions were evaluated in 100 metaphase
cells per sample by two independent cyto-
geneticists using coded slides. Chromatid
and chromosome breaks and chromatid
and chromosome exchanges were scored
according to Buckton and Evans (23) and
used to calculate the number ofcells carry-
ing aberrations per 100 cells (% CA). SCE
analysis was based on screening of 50
metaphase cells for each determination.
SCE were evaluated according to the
method ofPerry and Wolff(24).
CometAssayAnalysis
Lymphocytes for the comet assay were
isolated from 5 ml offresh heparinized
blood using Histopaque 1077. Cells were
washed in RPMI 1640 medium twice and
mixed with freezing medium containing
90% inactivated fetal calfserum and 10%
dimethyl sulfoxide (DMSO). The frozen
cells were stored in a polystyrene box at
-80OC; after 24 hr cells were stored in liq-
uid nitrogen until theywere thawed for the
assay. The comet assay was performed
according to Singh et al. (25) with a slight
modification (R Tice, personal communi-
cation). Briefly, fully frosted slides were
covered with the first layer of 1% agarose
(120 pI). The lymphocytes were diluted to
a density of 10,000 cells/slide and mixed
with 0.75% low melting-point agarose
(total volume 85 pl per slide). The second
layer ofagarose with cells was poured over
the first layer. Both layers ofagarose were
solidified at 40C. Lysis was carried out for
60 min (the lysing solution contained
2.5 M NaCl, 0.1 M Na2EDTA, 10 mM
Tris, 1% Triton X-100, 10% DMSO, pH
10), unwinding for 60 min, and elec-
trophoresis for 40 min at 20 V (0.67 V/cm,
300 mA). The same buffer was used for
both unwinding and electrophoresis (300
mM NaOH, 1 mM Na2EDTA, pH, 13.0),
and these procedures were performed at
40C under dim light. After electrophoresis
neutralizing buffer was applied (0.4 M
Tris, pH 7.5) and the nuclei were stained
with ethidium bromide (20 mg/ml), the
samples were analyzed using an image ana-
lyzer system (Comet, version 2.3; Kinetic
Imaging, Ltd, United Kingdom). The fol-
lowing comet parameters were evaluated
for 100 images per sample: percentage of
DNA in tail (T%), tail length (TL), and
tail moment (TM =T% xTL). Medians
ofthese parameters for 100 images were
used for the characterization of each
individual subject.
Determination of GSTM1Genotpe
The GSTM1 polymorphism was deter-
mined bypolymerase chain reaction (PCR)
with a slight modification (using DNA iso-
lated from WBC) described by Zhong et
al. (26). Two of the three primers used
could also anneal to another class Mgene
(GSTM4), while the third was specific for
the GSTMI gene. The GSTMI null geno-
type was identified on the basis of the
absence of the GSTMI-specific fragment.
The consistent presence ofthe other frag-
ment was used as an internal standard to
detect failure ofthe amplification reaction.
StaistclAnalysis
Statistical analysis was performed using
the STATGRAPHICS Plus 7.0 package
(Magnuistics, Inc., Rockville, MD). Non-
parametric methods were chosen for a
group-wide evaluation of the individual
data that did not follow a normal distribu-
tion. The Mann-Whitney rank sum U-test
was used for comparison of two samples
and the Kruskal-Wallis one-way analysis of
variance by ranks was used for evaluation
ofthe data in overall studies. Correlations
were performed by the Spearman rank cor-
relation test. Using log-transformed data,
the multifactor analysis ofvariances proce-
dure was used to analyze the association
between biomarkers and independent vari-
ables while controlling for the potential
influence ofthe othervariables.
Results
We report here the relationship between
biomarkers, analyzed in a pilot study, and
GSTMI genotype (Table 1). The GSTMI
gene was present in 48% ofTeplice non-
smokers and only in 37% of Prachatice
nonsmokers. In the group ofsmokers from
Teplice (n=9), there were only two persons
lacking the GSTMI gene; therefore, it was
not reasonable to evaluate smokers accord-
ing to the presence ofthis gene. We did not
observe any significant differences in DNA
and protein adducts, CA, and SCE between
GSTMJ-positive and -negative groups in
both districts. Asignificandy increased level
ofurinary PAHs and their metabolites were
observed in the GSTMJ-negative group
compared with GSTMI-positive group in
nonsmokers from Teplice. The elevated
exposure to carcinogenic PAHs by the
GSTMI-negative group, as determined by
personal air sampling, may have contri-
buted to the significant difference observed
in urine. In contrast, the elevated PAH
exposure by the GSTMI-positive group
from Prachatice was probably responsible
for the lack ofa difference in PAH/metabo-
lite levels in the urine samples between
these two groups. Nevertheless, the PAH
levels as determined by air monitoring and
in urine are higher for the Teplice group as
comparedwith the Prachatice group.
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Table 1. Effect of GSTM1 genotype on the biomarkers of dose and effect for nonsmokers from Teplice (polluted
region) and Prachatice (control region) analyzed in the pilot study.
Teplice Prachatice
GSTM1+ GSTM1- GSTM1+ GSTM1-
Biomarkers (n=10) (n=11) (n=11) (n=19)
DNAadducts per 108 nucleotides 4.00 4.22 4.77 3.86
(0.93-12.17)a (0.81-7.49) (1.05-9.58) (0.61-16.27)
Protein adducts, fm/mg protein 11.1 11.3 12.0 9.5
(9.0-29.5) (6.0-18.4) (6.0-15.7) (6.0-18.9)
Chromosomal aberrations, % 1.0 1.0 3.0 2.0
(0-4) (0-4) (0-6 (0-4)
Sisterchromatid exchanges 4.48 4.84 4.2 4.9
(3.4-6.6) (4.0-6.4) (3.5-5.1) (3.5-6.2)
Urinary PAH/metabolitesb 180.7 272.9* 137.1 131.3
(96-304) (112-357) (62-186) (60-215)
Carcinogenic PAHCexposure (ng/m3) 7.7 12.5 8.3 5.0
(2.9-22.6) (8.3-26.0) (3.2-13.3) (2.7-18.8)
aMedian (range). bUrinary parent PAHs and their metabolites are expressed as ng/mg creatinine. Ccarcinogenic
PAHs evaluated from personal monitors include chrysene, benzo[a]antharacene, benzo[b]fluoranthene,
benzo[k)fluoranthene, benzo[a]pyrene, dibenzo[a,h]anthracene, indeno[1,2,3-c,d]pyrene and benzo[ghi]perylene.
*p=0.037 comparing GSTM1-positive and -negative groups from Teplice (Mann-Whitney rank sum Utest).
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Figure 1. Personal exposure to carcinogenic PAHs and
biomarkers analyzed (see methods)for 4 sampling days
of the follow-up study (medians) during the winter sea-
son of 1993 to 1994. *p<0.01 comparison of sampling
on 30 November with samplings on 5 January and
1 February(Mann-Whitney rank sum Utest).
The results of urine mutagenicity
analyzed with respect to the presence of
the GSTMI gene for nonsmokers from
Teplice are in Table 2. The higher muta-
genic response observed in the null
GSTMI genotype group was significant
(p=0.033) only in strain YG 1041, which
contained elevated levels ofnitroreductase
and O-acetyltransferase activities (27)
using a microsuspension assay.
A further analysis ofthe effect ofexter-
nal personal exposures was conducted
by applying a multifactor analysis ofvari-
ance procedure to log-transformed data.
Considering personal exposure and adjust-
ing data for age, GSTMI genotype, and
diet (evaluated from the questionnaire as
Table 2. Effect of GSTM1 genotype on urinary muta-
genicity (medians and ranges) in nonsmokers from
Teplice.
GSTM1 + GSTM1-
Tester strain (n=10) (n=11)
TA98 _S9a 0.25' 0.38
(0.15-1.90) (0.15-1.73)
TA98+S9a 0.39 0.56
(0.15-1.84) (0.15-1.92)
YG1041 _S9a 0.50 0.50
(0.50-11.41) (0.50-66.18)
YG1041 +S9a 2.98 5.58
(0.50-19.96) (0.50-38.70)
MS-YG1041 -S9c 9.14 61.23*
(5.0-50.0) (9.6-419.1)
MS-YG1041 +S9c 18.6 36.3
(5.0-262.9) (5.0-410.4)
Urinary mutagenicity expressed as revertants per mil-
ligram creatinine. aPlate incorporation assay. bMedian
(range). CKADO microsuspension assay. *p=0.033
comparing GSTM1 positive and negative groups
(Mann-Whitney rank sum U-test).
the consumption offried or smoked meat
during 24 hr before collection ofblood),
the effect of the GSTMI genotype on
mutagenicity became less pronounced, but
its effect on the urinary PAH/metabolites
(Table 1) remained significant (p=0.030).
The follow-up repeated-measures study
was conducted with a group of 19 non-
smoking women from Teplice that were
sampled repeatedly for 4 additional sam-
pling days (all on the same day) during the
winter season of 1993 to 1994. Elevated
ambient concentrations of pollutants
exceeded the daily maximal acceptable
levels only on 1 day (30 November 1993)
ofthese samplings. The comet assay used
for evaluation ofDNA damage in lympho-
cytes was added as a new biomarker for the
follow-up study. A summary ofthe median
values for DNA adducts, CA, and comet
assay parameters (T% and TM) together
with personal exposures is shown in Figure
1. Personal exposures to carcinogenic
PAHs (p<0.01) were significantly higher
in the second sampling (30 November
1993) as compared with the first, third,
and fourth ones (median =36.2, compared
with 11.3, 13.7, and 12.6 ng/m3). There
was a significant effect (Kruskal-Wallis test:
p<0.01) ofsampling days on DNA adduct
levels and comet parameters T% and TM.
DNA adducts levels were elevated (p<0.05)
in the second sampling period (median =
6.54, compared to 4.07, 4.05, and 3.79
adducts/108 nucleotides). Comet parame-
ters T% and TM exhibited significantly
increased values (p<0.01) only in compar-
ison with the fourth sampling period (T%
median= 7.12, compared to 5.35; TM
median = 0.42, compared to 0.34). There
were no significant differences in CA
between sampling periods, which is consis-
tent with cumulative dose for a longer time
period, but there is a trend toward lower
CA following to the third and fourth
samplings (see Figure 1).
The average ambient concentrations of
carcinogenic PAHs for weeks and months
before sampling days in the follow-up
study are shown in Figure 2. The data
before the first sampling on 25 October
were not available. The highest differences
in the ambient PAH concentrations
between the second sampling and the two
additional samplings were on the day of
sampling (123.2 vs 30.1 and 32.3 ng/m3,
respectively); the differences in the 1-
week-before samplings were less (46.20
versus 28.98 and 6.44 ng/m3, respec-
tively). The average monthly concentra-
tions of ambient carcinogenic PAHs
before these sampling periods were very
similar (before the second: 27.9; third:
30.4, and fourth: 22.8 ng/m3).
In the overall follow-up study, a
significant correlation between individual
a)
- 140- A PAH-PEM
& 1201- * PAHdayofsample
X 1W PAHweekbefore
< 801 C PAH month before
8@ 40-
0
. = 20 j7
2. O C.) 250Oct 30Nov 5Jan iFeb
Figure 2. Average ambient exposure to carcinogenic
PAHs (in ng/m3; see Methods) during the sampling
days of the follow-up study and during 24 hr of sam-
pling, 1 week and 1 month before samplings.
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Table 3. Effect ofthe GSTM1 genotype on DNA adducts and comet assay parameters.
Parameters GSTM1+ GSTM1- Significancea
Overall studyb
Sample size 23 21
DNAadducts/108nucleotides 4.32(2.70-7.78)c 5.58(3.01-11.1) p=0.101
Carcinogenic PAHdexposure (ng/m3) 14.2 (5.3-76.0) 16.8(5.3-53.9) p=0.512
Follow-up studye
Sample size 32 33
DNA percentage in comet T(%) 6.07 (4.31-8.59) 7.03(3.39-10.09) p=0.002
TMf 0.35(0.16-0.80) 0.44(0.16-1.11) p=0.009
Carcinogenic PAHd'exposure (ng/m3) 13.9 (5.0-76.0) 16.8(4.3-304) p=0.189
'Mann-Whitney rank sum U-test. bOverall study of 10 nonsmoking women participating in a pilot study and 4 addi-
tional sampling days of follow-up study; the whole set of DNA samples was run in the same experiments (see
Methods) and the frequency of GSTM1 null genotype was 50%. cMedian (range). dCarcinogenic PAHs include
chrysene, benzo[a]anthracene, benzo[b]fluoranthene, benzo[klfluoranthene, benzo[a]pyrene, dibenzo[a,h]anthra-
cene, indeno[l,2,3-c,dlpyrene and benzo[ghi]perylene. 'Follow-up study of 19 nonsmoking women (4 sampling
days); frequency of GSTM1 null genotype was 53%. fTM=T(%)xTL(pm).
personal exposures to carcinogenic PAHs
and DNA adducts was found (r= 0.710;
p < 0.001). The comet parameter T(%)
correlated significandy (r=0.304;p=0.015)
with personal exposures to respirable parti-
cles (mass concentrations). The personal
24-hr exposures were unrelated to the
results ofcytogenetic analysis.
The frequency of the GSTMI null
genotype in the follow-up study group was
53%. Group-wide comparison resulted in
nonsignificant elevated DNA adduct levels
by the null GSTMI genotype group and
significant increased values of both the
comet parameters (Table 3). In a multifac-
tor analysis ofvariance, after accounting
for the PAH exposure, sampling, age, and
diet, the effect ofthe GSTMI genotype on
comet parameters became less pronounced
(Table 4).
Discussion
Biomarkers ofhuman exposure, dose, and
genetic effects in the general population
have recently been studied with respect to
exposures from environmental pollution
(5-7,11,13,28-32). Perera et al. (5) found
that the exposure to environmental pollu-
tion in the Silesian region of Poland was
associated with a significant increase of
DNA adducts, SCE, and CA, as well as
with a frequency of ras oncogene overex-
pression. In this study, DNA adducts were
significantly correlated with chromosomal
aberrations, providing a possible link
between environmental exposure and
genetic alterations relevant to diseases.
Autrup et al. (31) reported that nonsmok-
ing pregnant women living in a suburban
area had higher PAH-albumin adduct
levels than comparable women living in a
rural area. When the suburban and rural
groups were combined, the daily trans-
portation time of these women appeared
to be a major factor contributing to the
protein adducts, suggesting the importance
of exposure to incomplete combustion
products from either vehicle exhaust or
local heating. In this study, the GSTMI
genotype did not alter these PAH-protein
adduct levels. None of these studies
employed personal exposure monitoring to
quantitatively relate individual exposure
to specific air pollutants to the levels of
biomarkers analyzed.
The studies reported here have mea-
sured both ambient environmental levels of
airborne carcinogenic PAHs and personal
exposure to carcinogenic PAHs, which
in both cases are adsorbed to respirable
particles. The purpose ofthis study was to
determine the relationship between per-
sonal external exposure to PAHs and bio-
markers ofinternal exposure, dose, genetic
damage, and metabolic susceptibility. The
GSTMI genotype, reported here, is the first
metabolic susceptibility marker examined
in this population.
Only one ofthe sampling periods (the
second) in the follow-up study had sub-
stantially elevated ambient air pollution
where the 24-hr personal exposures to
PAHs (e.g., benzo[a]pyrene at 7.5 ± 3.6
ng/m3) reached values comparable to those
offoundry workers during an 8-hr shift
(6 ±3 ng/m3)(33). During most of the
winter period ofthis study (1993-1994),
unusually windy conditions prevented the
winter inversion episodes typical of the
Teplice district and surrounding districts
in northern Bohemia. For this reason, this
study will continue for several more years.
During three ofthe four repeated sampling
periods the personal exposures were
Table 4. Effects of exposure, sampling, GSTM1 geno-
type, age, and diet on DNA adducts and comet assay
parameters bymultifactoranalysisofvariance procedure.
Comet parameters
Factors DNAadducts T(%) TM
PAH exposure p=0.017 p=0.231 p=0.390
Sampling period p=0.113 p<0.001 p=0.024
GSTM1 genotype p=0.091 p=0.071 p=0.178
Age p=0.051 p=0.232 p=0.012
Diet p=0.970 p=0.112 p=0.115
relativelylowand comparable to those found
in other urban areas ofNorth America and
Europe. In spite ofthis, within the popula-
tion studied, there was a sufficiently high
interindividual variability in the personal
exposures to PAHs to permit correlation
analysis between individual personal expo-
sure and biomarker measures. In previous
studies comparing personal exposure and
ambient air concentrations of air pollu-
tants, it has been reported that such indi-
vidual variation in personal exposure
should be expected due to different micro-
environmental concentrations indoors and
outdoors and different times spent in each
microenvironment (9,15,16). For example,
the postal workers in Teplice have different
postal routes within the city that could
account for variability in their personal
exposures during working hours. During
nonworking hours, theyreturn to homes in
different sections ofthe city.
The Teplice nonsmokers in our pilot
study that lacked the GSTMI gene (null
genotype) exhibited significantly increased
levels of urinary PAH/metabolites and
increased urine mutagenicity in strain
YG1041 without metabolic activation
(direct acting mutagens) when group-wide
comparison was used. This finding is con-
sistent with the report that the urine of
smokers lacking this gene was several times
more mutagenic than that ofsmokers with
the gene (34). Since we had only two
smokers lacking the GSTMI gene, we were
unable to confirm this finding in smokers
in our study (n =9). Since GSTs are impor-
tant in the detoxification of PAHs and
other carcinogens by catalyzing conjuga-
tion of their reactive electrophilic forms
to glutathione, it is expected that individu-
als with the null genotype may be at
greater risk. The human polymorphism of
the GSTMI gene has been shown to be
associated with an increased risk of cancer
(35,36), as well as with susceptibility to
mutagen-induced cytogenetic damage
(37). When we analyzed the effect ofthe
GSTMI genotype on the other biomarkers
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in our pilot study (e.g., DNA adducts,
protein adducts, and cytogenetic markers)
by analysis ofvariance, we did not find a
relationship between the presence of the
GSTMI gene and the other biomarkers.
This may be due to the relatively small
sample size (n=21). It has been assumed
that lack ofthe GSTMI gene would result
in an increased level ofbinding ofgeno-
toxic compounds with cellular macromole-
cules (e.g., as measured by DNA and
protein adducts). In a study of Swedish
chimney sweeps, those with the GSTMI
null genotype had only slightly, but not
significantly, elevated DNA adduct levels
(38). No effect ofthe GSTMI genotype on
PAH-albumin adduct levels was reported
in the study of Danish pregnant women
exposed to urban airpollution (31).
In our study, we have examined the
relationship between the GSTMI genotype
and PAH exposure, DNA adducts, and the
DNA damage parameters as measured by
the comet assay. DNA adducts were
slightly, but not significantly, elevated in
the GSTMI null genotype. The comet
assay parameters (T% and TM) were both
significantly elevated (p<0.05) in the null
GSTMI genotype, consistent with a report
that GSTMI null individuals exposed
to epoxides have a higher induction of
cytogenetic damage (37).
In both studies the questionnaire data
were used to explore the other factors that
may affect interindividual variations seen in
the biomarker data such as age, consump-
tion offried or smoked foods, and exposure
to tobacco smoke due to passive smoking
during the 24-hr period ofsampling. These
parameters generallywere notsignificant.
In the above discussion ofthe influence
ofthe GSTMI genotype, the influence of
genotype is considered to be a single factor.
However, if we perform a multifactor
analysis ofvariance, considering exposure
and adjusting the data for GSTMI, age,
and diet, these significances disappear. If
you do not consider personal exposure,
then the group-wide comparison (Mann-
Whitney rank sum U-test) or one-way
analysis ofvariance (Kruskal-Wallis test)
will show an erroneously high significance
for the effect ofthe GSTMI null genotype,
such as on both comet parameters in our
study. Other biomarker studies in progress
will be analyzed by this more rigorous mul-
tifactor analysis method. These results
show the importance of considering all
potential factors that may affect the bio-
markers being analyzed. In the ideal case,
simultaneous biological and statistical
significance ofdifferences obtained should
be considered.
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